Last reviewed · How we verify
NCT03061110
Stromal Vascular Fraction for Treatment of Xerostomia
Phase 1, PHASE2 trial testing Stromal Vascular Fraction in Xerostomia Due to Radiotherapy (Disorder). Withdrawn.
28 December 2020
Quick facts
| Lead sponsor | Midwestern Regional Medical Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 November 2018 |
| Primary completion | 28 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stromal Vascular Fraction
- Usual Care
Conditions studied
- Xerostomia Due to Radiotherapy (Disorder) — all drugs for Xerostomia Due to Radiotherapy (Disorder) →
Sponsor
Midwestern Regional Medical Center
Who can join
21 and older, any sex, with Xerostomia Due to Radiotherapy (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, single center, double armed, randomized treatment with observation only (standard of care) control group. Subjects receiving study treatment will have 6 months of study follow-up. Stromal vascular fraction (SVF), an adipose-derived tissue preparation, will be injected into salivary glands to determine safety and efficacy to restore saliva production in head and neck cancer patients with chronic xerostomia resulting from radiation therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03061110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stromal Vascular Fraction
Trials testing the same drug.
- NCT03226093 — Safety Analysis of Implantation of Stromal Vascular Fraction · NA · completed
Other recruiting trials for Xerostomia Due to Radiotherapy (Disorder)
Currently open trials in the same condition.
- NCT07170358 — Screening of Biomarkers and Related Mechanisms for RIX · recruiting
- NCT06700863 — Screening of Biomarkers and Related Mechanisms for RIX · recruiting
Other Midwestern Regional Medical Center trials
Trials by the same sponsor.
- NCT02486796 — Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03061110 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Midwestern Regional Medical Center
- Last refreshed: 30 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03061110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing